Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Response to crizotinib observed in metastatic mediastinum lymph node from a non-small cell lung cancer patient harboring EZR-ROS1 fusion.

× No keyword cloud information.

5 in total

1. Silence of ezrin modifies migration and actin cytoskeleton rearrangements and enhances chemosensitivity of lung cancer cells in vitro.

Authors: Qing-Yong Chen; Wei Xu; De-Min Jiao; Li-Jun Wu; Jia Song; Jie Yan; Jian-Guo Shi
Journal: Mol Cell Biochem Date: 2013-02-22 Impact factor: 3.396

2. ROS1 rearrangements define a unique molecular class of lung cancers.

Authors: Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal: J Clin Oncol Date: 2012-01-03 Impact factor: 44.544

3. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

Authors: Kurtis D Davies; Anh T Le; Mariana F Theodoro; Margaret C Skokan; Dara L Aisner; Eamon M Berge; Luigi M Terracciano; Federico Cappuzzo; Matteo Incarbone; Massimo Roncalli; Marco Alloisio; Armando Santoro; D Ross Camidge; Marileila Varella-Garcia; Robert C Doebele
Journal: Clin Cancer Res Date: 2012-08-23 Impact factor: 12.531

4. Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Authors: Mark M Awad; Ryohei Katayama; Michele McTigue; Wei Liu; Ya-Li Deng; Alexei Brooun; Luc Friboulet; Donghui Huang; Matthew D Falk; Sergei Timofeevski; Keith D Wilner; Elizabeth L Lockerman; Tahsin M Khan; Sidra Mahmood; Justin F Gainor; Subba R Digumarthy; James R Stone; Mari Mino-Kenudson; James G Christensen; A John Iafrate; Jeffrey A Engelman; Alice T Shaw
Journal: N Engl J Med Date: 2013-06-01 Impact factor: 91.245

5. Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer.

Authors: Tiefeng Jin; Jingchun Jin; Xiangyu Li; Songnan Zhang; Yun Ho Choi; Yingshi Piao; Xionghu Shen; Zhenhua Lin
Journal: BMC Cancer Date: 2014-03-15 Impact factor: 4.430

5 in total

3 in total

Response to crizotinib observed in metastatic mediastinum lymph node from a non-small cell lung cancer patient harboring EZR-ROS1 fusion.

1. Silence of ezrin modifies migration and actin cytoskeleton rearrangements and enhances chemosensitivity of lung cancer cells in vitro.

2. ROS1 rearrangements define a unique molecular class of lung cancers.

3. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

4. Acquired resistance to crizotinib from a mutation in CD74-ROS1.

5. Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer.

Review 1. Interstitial Deletions Generating Fusion Genes.

2. CT-guided iodine-125 brachytherapy as salvage therapy for recurrent mediastinal lymph node metastasis.

3. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.